Wellbutrin SR Dosing: Once or Twice Daily
Wellbutrin SR (bupropion sustained-release) is FDA-approved for twice-daily dosing, not once-daily dosing, and must be administered as 150 mg twice daily (with the second dose before 3 PM) to achieve therapeutic efficacy and minimize insomnia risk. 1
FDA-Approved Dosing Schedule for Wellbutrin SR
Initiate with 150 mg once daily in the morning for the first 3 days, then increase to the target dose of 150 mg twice daily (total 300 mg/day), with at least 8 hours between doses. 1
The second daily dose must be taken before 3 PM to reduce insomnia risk, as bupropion's activating properties can interfere with sleep when dosed late in the day. 2, 3
The maximum dose is 400 mg/day (200 mg twice daily) for patients showing no clinical improvement after several weeks at 300 mg/day, though single doses should never exceed 200 mg to avoid high peak concentrations. 1
Why Twice-Daily Dosing Is Required for SR Formulation
Wellbutrin SR is bioequivalent to the immediate-release formulation only when dosed twice daily (150 mg BID equals 100 mg TID of immediate-release), maintaining steady-state exposure to bupropion and its active metabolites. 1
The SR formulation achieves peak plasma concentrations (Cmax) approximately 3 hours post-dose with an elimination half-life of 21 hours, requiring twice-daily administration to maintain therapeutic levels throughout the day. 1
SR and XL formulations are not interchangeable—each requires its specific dosing schedule (SR twice daily, XL once daily) to maintain safety and efficacy. 2, 3
Evidence on Once-Daily SR Dosing
One 1998 trial compared 150 mg once daily versus 150 mg twice daily (300 mg total) in depression and found both regimens superior to placebo, with once-daily dosing appearing "at least as effective" as twice-daily at the 150 mg total dose. 4
However, this finding applies only to the 150 mg total daily dose, not the standard 300 mg therapeutic target—the FDA label does not support once-daily dosing of SR at any dose. 1
A 2013 Asian study comparing 150 mg once daily and 300 mg/day (150 mg BID) found neither dose significantly superior to placebo in that population, though safety profiles were favorable. 5
Clinical Pitfalls to Avoid
Do not prescribe Wellbutrin SR once daily at 300 mg—this deviates from FDA-approved dosing, lacks supporting efficacy data, and may result in subtherapeutic exposure or increased seizure risk from excessive peak concentrations. 1
Patients who cannot adhere to twice-daily dosing should be switched to Wellbutrin XL 300 mg once daily in the morning, which is FDA-approved for once-daily administration and bioequivalent to SR 150 mg twice daily. 2, 3, 6
Administering the second SR dose after 3 PM markedly increases insomnia risk without providing benefit—strict adherence to the before-3-PM timing is essential. 2, 3
When to Choose SR Over XL
Patients unable to swallow large tablets whole may prefer the smaller SR tablets, which are easier to ingest. 2
Individuals requiring flexible dosing (e.g., 150 mg total daily) may find SR easier to titrate, as each tablet represents a single 150 mg dose unit. 2
SR and XL formulations have equivalent efficacy and adverse event profiles when dosed according to their respective schedules, so the choice is primarily based on convenience and patient preference. 6, 7
Absolute Contraindications (All Bupropion Formulations)
Seizure disorder or any condition lowering seizure threshold (stroke, brain metastases, eating disorders such as anorexia or bulimia) is an absolute contraindication—bupropion carries approximately 0.1% seizure risk at therapeutic doses. 2, 3, 1
Current or recent (within 14 days) MAOI use is contraindicated due to hypertensive crisis risk. 1
Abrupt discontinuation of alcohol or benzodiazepines contraindicates bupropion due to seizure risk. 2, 3
Concurrent tamoxifen therapy is contraindicated because bupropion inhibits CYP2D6, reducing tamoxifen efficacy. 2, 3
Monitoring and Response Timeline
Intensive neuropsychiatric monitoring is required during the first 1–2 weeks, assessing for suicidal ideation, agitation, irritability, akathisia, worsening anxiety, panic, hostility, and impulsivity—the highest risk period is the first 1–2 months. 2, 3
Initial energy or activation improvements may appear within days to weeks, but a full therapeutic trial requires 4–8 weeks at adequate doses. 2, 3
Reassess treatment adequacy at 6–8 weeks—do not deem bupropion ineffective before completing this trial period. 2, 3
Common Adverse Effects with SR 150 mg Twice Daily
The most frequently reported adverse effects are loss of appetite, insomnia, anxiety, agitation, dry mouth, headache, nausea, constipation, and tremor. 2, 3
Bupropion is associated with significantly lower sexual dysfunction rates (≈8%) compared with SSRIs (18–30%), making it preferable when sexual side effects are a primary concern. 2, 3, 6